Hims Hers Health is trading 4.1% lower at $24.93 in pre-market, with no confirmed direct catalyst identified. - Its Q3 2026 report is scheduled after the market close on November 9. It is still upcoming and does not explain the decline as a reported earnings result. - November 6 Lilly partnership news was associated with Friday’s rally, not a clear explanation for Monday’s drop. - Healthcare is up 1.90% pre-market, so sector weakness does not account for the move.